59.8 F
New York
Friday, September 29, 2023

Biolingus, oral GLP-1 diabetes drug developer, files for $47M IPO

Must read

Share Me


Syringe and medical drugs for diabetes, metabolic disease treatment


Biolingus (SUBL), which is developing orally administered versions of GLP-1 diabetes drugs, has filed for a proposed $47M US initial public offering.

The Switzerland-based biotech company said in a filing that it is looking to offer 3M shares priced between $15


Source link

- Advertisement -spot_img

More articles


Please enter your comment!
Please enter your name here

Latest article